Bristol-Myers Squibb Co (BMY)
44.02
+0.12
(+0.27%)
USD |
NYSE |
May 07, 16:00
43.91
-0.11
(-0.25%)
After-Hours: 18:11
Bristol-Myers Squibb Net Income (Quarterly): -11.91B for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -11.91B |
December 31, 2023 | 1.762B |
September 30, 2023 | 1.928B |
June 30, 2023 | 2.073B |
March 31, 2023 | 2.262B |
December 31, 2022 | 2.022B |
September 30, 2022 | 1.606B |
June 30, 2022 | 1.421B |
March 31, 2022 | 1.278B |
December 31, 2021 | 2.372B |
September 30, 2021 | 1.546B |
June 30, 2021 | 1.055B |
March 31, 2021 | 2.021B |
December 31, 2020 | -10.03B |
September 30, 2020 | 1.872B |
June 30, 2020 | -85.00M |
March 31, 2020 | -775.00M |
December 31, 2019 | -1.056B |
September 30, 2019 | 1.353B |
June 30, 2019 | 1.432B |
March 31, 2019 | 1.71B |
December 31, 2018 | 1.16B |
September 30, 2018 | 1.901B |
June 30, 2018 | 373.00M |
March 31, 2018 | 1.486B |
Date | Value |
---|---|
December 31, 2017 | -2.328B |
September 30, 2017 | 845.00M |
June 30, 2017 | 916.00M |
March 31, 2017 | 1.574B |
December 31, 2016 | 894.00M |
September 30, 2016 | 1.202B |
June 30, 2016 | 1.166B |
March 31, 2016 | 1.195B |
December 31, 2015 | -197.00M |
September 30, 2015 | 706.00M |
June 30, 2015 | -130.00M |
March 31, 2015 | 1.186B |
December 31, 2014 | 13.00M |
September 30, 2014 | 721.00M |
June 30, 2014 | 333.00M |
March 31, 2014 | 937.00M |
December 31, 2013 | 726.00M |
September 30, 2013 | 692.00M |
June 30, 2013 | 536.00M |
March 31, 2013 | 609.00M |
December 31, 2012 | 925.00M |
September 30, 2012 | -711.00M |
June 30, 2012 | 645.00M |
March 31, 2012 | 1.101B |
December 31, 2011 | 852.00M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-11.91B
Minimum
Mar 2024
2.372B
Maximum
Dec 2021
107.45M
Average
1.489B
Median
Net Income (Quarterly) Benchmarks
Amgen Inc | -113.00M |
Gilead Sciences Inc | -4.17B |
Johnson & Johnson | 3.255B |
Karuna Therapeutics Inc (DELISTED) | -113.82M |
2seventy bio Inc | -56.82M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 11.86B |
Total Expenses (Quarterly) | 10.35B |
EPS Diluted (Quarterly) | -5.89 |
Enterprise Value | 135.05B |
Gross Profit Margin (Quarterly) | 75.29% |
Profit Margin (Quarterly) | -100.4% |
Earnings Yield | -7.04% |
Operating Earnings Yield | 8.04% |
Normalized Earnings Yield | 1.755 |